11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
May 2026 in “International Journal of Homoeopathic Sciences” Individualized Homeopathic Medicine shows promise for treating alopecia with lasting hair regrowth.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
2 citations
,
January 2024 in “Annals of Dermatology” Winter-onset alopecia areata patients are more likely to regrow hair within a year compared to spring-onset patients.
4 citations
,
June 2023 in “Frontiers in immunology” JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations
,
December 2020 in “Dermatology Archives” Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
April 2026 in “International Journal of Drug Delivery Technology” Alopecia can often be managed effectively with various treatments, but early diagnosis is crucial for preventing permanent hair loss.
November 2025 in “Journal of Pharmaceutical Research International” Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
March 2023 in “Pakistan Journal of Medical & Health Sciences” Vitamin D analogues can significantly help hair regrowth in Alopecia Areata patients.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
39 citations
,
January 2017 in “Dermatologic Therapy” Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
10 citations
,
July 2019 in “Indian Journal of Dermatology” Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
2 citations
,
August 2022 in “JAAD case reports” COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
December 2025 in “Chinese Medical Journal” Experts recommend starting systemic treatment for alopecia areata when the condition is severe or causes significant distress.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
May 2024 in “JEADV Clinical Practice” A change in SALT scores of 42 or 43 indicates meaningful improvement in alopecia areata treatment.
February 2026 in “Journal of the American Academy of Dermatology” Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.
November 2025 in “Frontiers in Medicine” Baseline severity and relapse history affect alopecia areata treatment and recurrence.